# Carlos L. Arteaga

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/carlos-l-arteaga/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,280 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 124 |
| i10-index | 393 |
| Last Known Institution | Southwestern Medical Center |
| OpenAlex ID | https://openalex.org/A5043946489 |
| ORCID iD | https://orcid.org/0000-0003-0870-9586 |
| Works | 1,327 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors](https://scholariq.org/papers/bim-expression-in-treatment-naive-cancers-predicts-responsiveness-to-kinase/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.